LGT Capital Partners’s ResMed RMD Stock Holding History

LGT Capital Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-107,130	Closed	-$24M	–	41
2026 Q1	$24M	Sell	107,130 -4,907	-4%	-$1.22M	1.28%	29
2025 Q4	$27M	Sell	112,037 -25,752	-19%	-$6.59M	1.34%	26
2025 Q3	$37.7M	Sell	137,789 -267,779	-66%	-$73.1M	1.83%	21
2025 Q2	$105M	Sell	405,568 -62,275	-13%	-$14.9M	4.63%	4
2025 Q1	$105M	Sell	467,843 -37,993	-8%	-$8.87M	4.65%	5
2024 Q4	$116M	Sell	505,836 -14,280	-3%	-$3.44M	4.4%	6
2024 Q3	$127M	Sell	520,116 -43,891	-8%	-$9.81M	4.42%	6
2024 Q2	$108M	Sell	564,007 -74,299	-12%	-$15.1M	3.68%	8
2024 Q1	$126M	Sell	638,306 -45,457	-7%	-$8.33M	3.95%	7
2023 Q4	$118M	Buy	+683,763	New	+$105M	3.51%	10

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

LGT Capital Partners's RMD Position: Q2 2026 in Review

LGT Capital Partners sold out of ResMed (RMD) in Q2 2026, closing a stake of 107,130 shares — an estimated $24M sold.

LGT Capital Partners first reported a position in RMD in Q4 2023 and held it in 10 quarters. The position peaked at $127M in Q3 2024. 885 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

LGT Capital Partners reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
LGT Capital Partners sold 107,130 ResMed shares in Q2 2026, an estimated $24M.
LGT Capital Partners first reported a position in ResMed in Q4 2023 and held it in 10 quarters.
LGT Capital Partners's ResMed position peaked at $127M in Q3 2024.
885 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on LGT Capital Partners's 13F filing for Q2 2026, filed 5 Aug 2026.